Fresenius, DE0005785604

Fresenius stock gains 0.35 percent to EUR 45.895 in Xetra trading

Published on 09/25/2026 at 18:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock was last at EUR 45.895 in Xetra trading at 4:24 p.m. CET on September 25, 2026, up 0.35 percent. The DAX and Euro Stoxx 50 were each up 0.6 percent in the market snapshot.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht
Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock was last at EUR 45.895 in Xetra trading at 4:24 p.m. CET on September 25, 2026, up 0.35 percent or EUR 0.160. Fresenius announced a EUR 54 million expansion of IV-fluid capacity in Poland and Italy. The DAX and Euro Stoxx 50 each stood 0.6 percent higher in the September 25 market snapshot.

The Xetra session on September 25, 2026 in figures

Fresenius SE & Co. KGaA (ISIN DE0005785604) traded at EUR 45.895 on Xetra at 4:24 p.m. CET. The quoted move was EUR 0.160, equal to a gain of 0.35 percent. The Xetra figure put the shares above the EUR 45.735 reference level implied by the reported absolute move. The session reading placed Fresenius below the DAX gain of 0.6 percent by 0.25 percentage points.

The DAX stood at 25,409 points in the September 25 market snapshot. The Euro Stoxx 50 reached 6,313 points at the same snapshot. Oil was listed at USD 106.2, down 0.4 percent, while gold stood at USD 4,282, up 0.1 percent. The euro was quoted at USD 1.1389, up 0.1 percent.

Capacity investment and UBS support the September 25 backdrop

finanzen.net reported on September 25, 2026, that Fresenius expanded IV-fluid capacity in Poland and Italy with EUR 54 million of investment. Fresenius opened a new production line in Kutno, Poland. Fresenius also expanded production and warehouse infrastructure in Isola della Scala, Italy. The investment provided the clearest dated company development in the session.

MarketScreener reported on September 17, 2026, that UBS maintained a Buy rating and a EUR 56 price target. Analyst Graham Doyle viewed clinical specialty nutrition as particularly undervalued after investor discussions with management. UBS also described the mAbxience biosimilar business as strategically important.

DAX, Euro Stoxx 50 and market factors on September 25, 2026

The DAX was at 25,409 points, up 0.6 percent, in the market snapshot accompanying the September 25 report. The Euro Stoxx 50 was at 6,313 points, also up 0.6 percent. Nasdaq was listed at 26,939 points, unchanged in that snapshot. Oil was at USD 106.2, down 0.4 percent, and the euro was at USD 1.1389, up 0.1 percent.

Fresenius lagged the DAX by 0.25 percentage points at the Xetra reading of 4:24 p.m. CET. The stock was last shown at EUR 45.895, while the reported daily move was EUR 0.160. The market figures placed European equities higher alongside a modestly weaker oil price. Fresenius trading therefore combined company investment news with a positive broad-market backdrop.

Disclaimer...

en | DE0005785604 | FRESENIUS | boerse | 70184626 | bgmi